share_log

Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target

Benzinga ·  Jun 13 00:16

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment